Catabasis Pharmaceuticals, Inc. (CATB) Research

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic treatments primarily within the United States. Their leading experimental drug, edasalonexent, is an oral small molecule undergoing Phase III clinical trials for Duchenne Muscular Dystrophy (DMD), functioning by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells. Additionally, the company is developing CAT-5571 as a potential treatment for cystic fibrosis. Catabasis also engages in collaborative research, including a preclinical partnership with the Jain Foundation to investigate edasalonexent for dysferlinopathy, and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 for both drug-sensitive and drug-resistant tuberculosis. The company was established in 2008 and is based in Boston, Massachusetts.

Market snapshot

Symbol
CATB
Price
$8.54
Day change
-6.97%
Market cap
$234.9M
52-week range
8.48-9.21
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Cytocom, Inc. (CBLI)
  • Celularity Inc. (CELU)
  • CARGO Therapeutics, Inc. Common Stock (CRGX)
  • Inhibrx Biosciences, Inc. (INXB)
  • Inozyme Pharma, Inc. (INZY)
  • Merrimack Pharmaceuticals, Inc. (MACK)
  • Acelyrin, Inc. (SLRN)
  • Spectrum Pharmaceuticals, Inc. (SPPI)

Recent insider activity

  • Harshbarger Benjamin — A-Award (200000 shares) on 2021-06-08
  • Callori Fred — A-Award (85000 shares) on 2021-06-02
  • Violin Jonathan — A-Award (85000 shares) on 2021-06-02
  • Clauser Noah — A-Award (600000 shares) on 2021-06-02
  • KISHBAUCH MICHAEL D — A-Award (100000 shares) on 2021-06-02

Open Catabasis Pharmaceuticals, Inc. (CATB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.